On June 10, 2025, Lisata Therapeutics, Inc. held its Annual Meeting where stockholders re-elected two directors, approved an amendment to the Employee Stock Purchase Plan increasing shares from 113,333 to 158,333, ratified Grant Thornton LLP as the accounting firm, and voted on executive compensation frequency.